Foghorn Therapeutics Will Discontinue The Independent Development Of FHD-286 In Combination With Decitabine For Relapsed/Refractory Acute Myeloid Leukemia. Foghorn Is Evaluating Partnerships And Investigator Sponsored Trials To Advance FHD-286
Benzinga Newsdesk 1 year ago
BiotechNewsHealth CareGeneral
The Company will prioritize its proprietary pipeline and Lilly collaboration programs, including the clinical-stage selective SMARCA2 (BRM) inhibitor FHD-909 (LY4050784).
The Company will prioritize its proprietary pipeline and Lilly collaboration programs, including the clinical-stage selective SMARCA2 (BRM) inhibitor FHD-909 (LY4050784).